Innovaderm Research Inc.
Sukhbir Kaur is an experienced professional in the field of Computerized Systems Validation, currently serving as Associate Director at Innovaderm Research Inc. since October 2021, where responsibilities include developing strategies for quality standards and regulatory compliance in clinical trial computerized systems. Prior experience includes roles at Taro Pharmaceuticals, focusing on validation of various systems, and at Deloitte, where Sukhbir coordinated SAP ECC implementations across multiple countries using different methodologies. Sukhbir's career began at the Indian Council of Medical Research, managing quality control activities and training staff on GLP and GCP compliance. Educational qualifications include a Master's degree in Molecular Biology and Biochemistry, ISO 15189:2007 certification, and ITIL Foundation Level certification.
This person is not in any teams
This person is not in any offices
Innovaderm Research Inc.
1 followers
As a CRO (Clinical Research Organization) specialized in dermatology, we provide scientific guidance, accurate results and customer satisfaction. Our unique service offering combines specialized Contract Research Services, knowledge of dermatology sites in North America and Europe reach and the extended capabilities of a large clinical research site. The design and conduct of Phase 1 to Phase IV studies in Dermatology is our core expertise. Our specialized services include: • Study Design and Protocol Development • Submission to Regulatory Agencies and Central Ethics Committees • Regulatory Consulting • Trial Master Files Management • Project Management • Investigator / Site Selection • Patient Recruitment • Clinical Monitoring • Medical Monitoring • Pharmacovigilance • Data Management • Biostatistical Analysis • Clinical Study Report • Medical Writing / Publication Since 2000, Innovaderm has built a strong reputation for the quality of its research and the care offered to its study participants, its clients and its sites, often exceeding our client’s timeline expectations.